NorthWest Biotherapeutics Inc (NWBO)

[Nemesis18]

Sir, In regards to ‘psuedoprogression’, shown in those who had the ‘vaccine’ , what were the OS rates ?

And presuming that this inflammatory response was probably short lived, why the need to change endpoints ?

This juncture in the trial, needs further close regulatory examination imho, as does ..

Did the Vaccine reduce the median OS in favourable genomic subgroups, and or those with more favourable histology ?

Where’s the IDH status for each patient ?
Mine was ‘Wildtype’…., and in the Who Reclassification, this info was critical to my re-diagnosis, nine years after the original.